Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Advanced KIT-mutant Melanoma Following Progression on Standard Therapy: a Phase I/II Trial

NCT04546074 is registered in ClinicalTrials.gov with Keio University as lead sponsor.

NCT NCT04546074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04546074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Advanced KIT-mutant Melanoma Following Progression on Standard Therapy: a Phase I/II Trial
Lead sponsor
Keio University
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 14, 2020
Completion date
October 31, 2025
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma